SCHEDULE: Farallon Capital Amends Minerva Neurosciences Stake

Sentiment:

Beneficial Ownership Update 5 February 2026 2:51 PM

📋All filings for Minerva Neurosciences, INC

Farallon Capital Management and its affiliates updated their beneficial ownership in Minerva Neurosciences, Inc., reflecting personnel changes and a 9.99% aggregate stake.

Summary

Farallon Capital Management and its affiliated funds and individuals (collectively, "Reporting Persons") filed an Amendment No. 1 to their Schedule 13G regarding Minerva Neurosciences, Inc. common stock.
The Reporting Persons collectively beneficially own 4,539,854 shares of Minerva Neurosciences, Inc. common stock.
This aggregate ownership represents 9.99% of the issuer's class of securities.
The ownership includes 2,365,000 directly held shares and the right to acquire up to 2,174,854 additional shares upon conversion of Series A Preferred Stock, which are acquirable through Preferred Tranche A Warrants.
A Beneficial Ownership Limitation restricts conversion of Series A Preferred Stock if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
The filing also reports changes in the managing members of Farallon's general partner entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It primarily serves as a routine disclosure of beneficial ownership and internal personnel changes within the reporting entity, Farallon Capital, without providing new material information about Minerva Neurosciences' operational or financial performance.

Positives

Farallon Capital, a significant institutional investor, maintains a substantial 9.99% stake in Minerva Neurosciences, Inc., indicating continued confidence in the company.
The filing explicitly states that the securities were not acquired for the purpose of changing or influencing control of the issuer, which may suggest a long-term investment perspective rather than an activist one, potentially reducing immediate governance uncertainty.

Risks

The Beneficial Ownership Limitation of 9.99% on Series A Preferred Stock conversion means that Farallon's ability to increase its voting power through these instruments is capped, potentially limiting its influence if it desired more.
While the filing states the shares were not acquired for control, it does mention "activities solely in connection with a nomination under §§ 240.14a-11," which could imply potential future engagement in proxy contests or board nominations, introducing a degree of governance risk or uncertainty for existing management.

Future Outlook

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership stakes, which can be a signal of investor confidence or strategic positioning within the biotechnology or pharmaceutical sector, where Minerva Neurosciences operates. While Farallon's stated intent is not to influence control, a 9.99% stake is a notable position for any institutional investor in a publicly traded company.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Managing Member/Manager of Farallon General Partner entities	NA	Avner A. Husen	2026-01-01	Became a managing member/manager, thus deemed a beneficial owner.
Managing Member/Manager of Farallon General Partner entities	Richard B. Fried	NA	2025-12-31	Ceased to be a managing member/manager, thus no longer deemed a beneficial owner.
Managing Member/Manager of Farallon General Partner entities	Rajiv A. Patel	NA	2025-12-31	Ceased to be a managing member/manager, thus no longer deemed a beneficial owner.
Managing Member/Manager of Farallon General Partner entities	William Seybold	NA	2025-12-31	Ceased to be a managing member/manager, thus no longer deemed a beneficial owner.

Stakeholder Impact

Shareholders: The disclosure of a significant institutional stake (9.99%) by Farallon Capital provides transparency regarding a major investor's position. The statement that the shares were not acquired for control, but potentially for nominations, could be interpreted differently by various shareholders.
Management: The explicit statement about not seeking control, but potentially engaging in nominations, suggests Farallon may seek to influence governance through board representation, which could impact current management.

Key Dates

Date	Description
2025-12-31	Date of event requiring the filing of this statement; also the effective date for Richard B. Fried, Rajiv A. Patel, and William Seybold ceasing to be managing members/managers of Farallon's general partner entities.
2026-01-01	Effective date for Avner A. Husen becoming a managing member/manager of Farallon's general partner entities.
2026-02-05	Date of signing and filing of this Amendment No. 1 to Schedule 13G.

Recommendation

hold

This Schedule 13G amendment primarily updates the beneficial ownership stake of Farallon Capital in Minerva Neurosciences and reports internal personnel changes within Farallon. It does not provide new fundamental information about Minerva Neurosciences' operations, financial performance, or strategic direction that would warrant a change in investment thesis. The 9.99% stake is significant but has been previously disclosed, and the stated intent is not to influence control, suggesting a stable, long-term institutional position. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for significant upside or downside based solely on this filing.

Keywords

Minerva Neurosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Equity Stake, Preferred Stock, Warrants

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.